Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 15/20 | 0.38 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.36 |
| ▸ | TPSD1 | Q9BZJ3 | 2/20 | 0.36 |
| ▸ | TPSG1 | Q9NRR2 | 2/20 | 0.36 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.35 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.35 |
| ▸ | F2 | P00734 | 1/20 | 0.35 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 1/20 | 0.34 |
| ▸ | JAK1 | P23458 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14243052 | 0.94 | TPSAB1 (0.42) | HRH3TPSAB1TPSD1TPSG1F2 | |
| SCHEMBL17888249 | 0.86 | JAK2 (0.36) | HRH3JAK2JAK1 | |
| SCHEMBL17888257 | 0.84 | GPR119 (0.42) | JAK2JAK1 | |
| SCHEMBL7447957 | 0.81 | MAPT (0.45) | — | |
| SCHEMBL17886601 | 0.81 | PDK4 (0.35) | HRH3TPSAB1TPSD1TPSG1F2 | |
| SCHEMBL21078142 | 0.81 | PRSS1 (0.35) | HRH3TPSAB1TPSD1TPSG1F2 | |
| SCHEMBL19226371 | 0.80 | HRH3 (0.41) | HRH3 | |
| SCHEMBL6079220 | 0.80 | L3MBTL1 (0.39) | — | |
| SCHEMBL14242829 | 0.77 | SLC6A15 (0.39) | TPSAB1TPSD1TPSG1PRSS1JAK2 | |
| SCHEMBL14243401 | 0.75 | GRM5 (0.44) | HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2016-06-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185780-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | HRH3 1610/4885TPSAB1 730/4885TPSD1 509/4885 |
| US-20170226132-A1 | TRIAZOLOPYRIDINE COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF | ABL1, JAK2, JAK1 | HRH3 1610/4885TPSAB1 730/4885TPSD1 509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.